Spiriva Dosing
For adults with COPD, use Spiriva HandiHaler 18 mcg (one capsule) once daily OR Spiriva Respimat 5 mcg (two puffs of 2.5 mcg) once daily; for adults and adolescents ≥12 years with asthma, use Spiriva Respimat 2.5 mcg (two puffs of 1.25 mcg) once daily; for children aged 6-11 years with asthma, use Spiriva Respimat 2.5 mcg once daily; and monitor patients closely with severe renal impairment (creatinine clearance <30 mL/min) for anticholinergic side effects, though no formal dose adjustment is specified. 1
COPD Dosing
The FDA-approved dose for COPD maintenance therapy is:
- HandiHaler device: 18 mcg (one capsule) inhaled once daily 1
- Respimat device: 5 mcg (two inhalations of 2.5 mcg) once daily 1
Both formulations provide similar systemic exposure and achieve steady-state within 7 days without accumulation 1. The terminal half-life is approximately 25 hours, supporting once-daily dosing 1.
Asthma Dosing
Adults and Adolescents (≥12 years)
Spiriva Respimat 2.5 mcg once daily (two puffs of 1.25 mcg each) is the approved dose for asthma 1, 2. This is notably lower than the COPD dose, as clinical trials demonstrated that 2.5 mcg provided superior pulmonary function outcomes compared to the 5 mcg dose in asthma patients 3. The 5 mcg dose showed efficacy but was less effective overall than the 2.5 mcg dose for asthma-specific endpoints 4.
Children (6-11 years)
Spiriva Respimat 2.5 mcg once daily is approved for children aged 6 years and older with asthma 5, 2. Studies in school-age children (6-11 years) demonstrated improved lung function with this dose 5.
Pediatric Considerations
- HandiHaler is not indicated for pediatric use 1
- Safety and effectiveness have not been established in children under 6 years 1
Renal Impairment Adjustments
No formal dose adjustment is recommended, but close monitoring is required for patients with moderate to severe renal impairment 1:
- Mild impairment (CrCl 60-<90 mL/min): 6-23% higher drug exposure; generally well-tolerated 1
- Moderate impairment (CrCl 30-<60 mL/min): 54-57% higher drug exposure; monitor closely for anticholinergic effects 1
- Severe impairment (CrCl <30 mL/min): 94% higher AUC and 52% higher Cmax after IV administration; insufficient inhalation data but monitoring essential 1, 6
The increased exposure occurs because tiotropium is predominantly renally excreted (74% unchanged in urine), with renal clearance exceeding creatinine clearance due to active tubular secretion 1, 6.
Monitoring Parameters in Renal Impairment
Watch for anticholinergic side effects including:
- Dry mouth
- Urinary retention
- Constipation
- Glaucoma symptoms 4
Key Clinical Pearls
Device-specific considerations: The HandiHaler requires inspiratory flow rates as low as 20 L/min, making it suitable for patients with severely compromised lung function (median PIF 30 L/min in COPD patients with FEV1 as low as 16% predicted) 1.
Timing flexibility: Bronchodilation lasts at least 24 hours, and the timing of daily administration does not affect efficacy 4.
No hepatic adjustment needed: Effects of hepatic impairment have not been studied, but given minimal hepatic metabolism (only 25% of dose undergoes CYP450 metabolism), dose adjustment is unlikely necessary 1.
Geriatric patients: No dose adjustment required despite age-related decreases in renal clearance, as this did not result in clinically significant increases in drug exposure 1.